The 20 Best Familial Prostate Cancer Doctors Near Me in Rosedale, MD

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Carducci is board certified in American Board Of Internal Medicine.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer. Dr. Civelek is board certified in American Board Of Nuclear Medicine.

"Dr. Patrick C. Walsh is a professor of urology at the Johns Hopkins School of Medicine. He is recognized internationally as a pioneer in the diagnosis and treatment of prostate cancer. Dr. Walsh is best known for his pioneering work in the development of ""the anatomic approach to radical prostatectomy,"" which involves nerve-sparing techniques that have reduced the probability of impotence and incontinence, and for his 30 years as director of the Brady Urological Institute. He has also made major contributions to the basic understanding of benign and malignant neoplasms of the prostate. Along with co-workers, he was the first to describe the 5 alpha-reductase enzyme deficiency, to develop an experimental technique for the induction of benign prostatic hyperplasia, to demonstrate the influence of reversible androgen deprivation on BPH, and to characterize hereditary prostatic cancer. Dr. Walsh received his undergraduate and medical training at Case Western Reserve University. After an internship and junior residency in surgery at the Peter Bent Brigham Hospital in Boston, he conducted an assistant residency in pediatric surgery at The Children''s Hospital Medical Center in Boston, and a residency in urology as well as a fellowship in endocrinology at the University of California Los Angeles, School of Medicine. He joined the faculty of Johns Hopkins in 1974. In 2004 he was named University Distinguished Service Professor of Urology. Dr. Walsh has received dozens of national and international awards and honors. He has authored or co-authored more than 600 articles and three books, including a best-seller for lay people titled The Prostate: A Guide for Men and the Women Who Love Them. For 25 years he was the editor-in-chief of Campbell''s Textbook of Urology, which has been renamed in his honor. He is on the editorial board of the New England Journal of Medicine, is a member of numerous international professional organizations and has served as the president of both the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons.". Dr. Walsh is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer and Prostate Cancer.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy. Dr. Pavlovich is board certified in American Board Of Urology.

Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. Dr. Song is board certified in American Board Of Radiology.

Dr. Misop Han is David Hall McConnell Professor of Urology and Oncology at the Johns Hopkins School of Medicine. Dr. Han is a urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. He specializes in robotic nerve-sparing prostatectomy and robotic nephrectomy. Dr. Han received his undergraduate and medical degrees at Johns Hopkins. After an internship in surgery and residency in urology, also at Johns Hopkins, he worked as faculty at Northwestern University and Hospital in Chicago, Illinois. In 2006, he joined the Johns Hopkins faculty. His research interests include the outcome of radical prostatectomy, medical robotics and prediction modeling (what happens to men following surgery for prostate cancer). He has published extensively in these subjects and has received international and national recognition for his research. He is actively involved in several clinical research projects with the database of more than 20,000 men who received surgery for prostate cancer at The Johns Hopkins Hospital. He is a member of the American Urological Association and the American Medical Association. Dr. Han is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Ureterocele, Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Han is board certified in American Board Of Urology.

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Denmeade is board certified in American Board Of Internal Medicine.

William Houck is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Houck is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Houck is board certified in American Board Of Internal Medicine.

William Dowling is a Urologist practicing medicine in Rosedale, Maryland. Dr. Dowling is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Enlarged Prostate (BPH), UPJ Obstruction, and Ureteroscopy.

Stephen Ronson is a Radiation Oncologist practicing medicine in Rosedale, Maryland. Dr. Ronson is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor.

Kelly Orwat is a Radiologist practicing medicine in Rosedale, Maryland. Dr. Orwat is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Metastatic Brain Tumor, and Primitive Neuroectodermal Tumor (PNET).

Dr. Edward Wright is an associate professor of urology at the Johns Hopkins School of Medicine. He serves as the Director of Urology at the Johns Hopkins Bayview Medical Center. His clinical and research interests are in male and female urinary incontinence, complex voiding dysfunction and pelvic genitourinary reconstructive surgery. His specialty has less to do with surgical removal and more with mending urological body parts and restoring functionality in them. His passion for Johns Hopkins lies in the fact that it is the type of place where things can be done, and patients’ questions can be answered and solutions to their problems can be found through all of the resources Johns Hopkins has to offer. Dr. Wright earned his M.D. from Dartmouth Medical School in New Hampshire. He completed his residency in urology at The Presbyterian Hospital in the City of New York and performed a fellowship in Urogynecology at Duke University School of Medicine. Dr. Wright is a member of the American Urologic Association and the Mid-Atlantic Section of American Urologic Association as well as the Society for Urodynamics and Female Urology. He has been recognized with a number of awards including Winner of the Urology Chief Resident's debate New York section of the American Urologic Society at the The New York Academy of Medicine. Dr. Wright is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Stress Urinary Incontinence, Urinary Incontinence, Neurogenic Bladder, Osteotomy, and Ureteroscopy. Dr. Wright is board certified in American Board Of Urology.

Dr. Marisa Clifton is the Director of Women’s Health at the Brady Urological Institute. She is fellowship trained. As a leader in the field of female urology, her clinical expertise includes surgical and nonsurgical treatment of pelvic organ prolapse, stress urinary incontinence, urgency urinary incontinence, urinary fistulas, genitourinary reconstruction and urethral diverticula. Dr. Clifton is also an Assistant Professor of Urology at the Johns Hopkins School of Medicine and serves as the Director of Robotic Education. In addition, she serves as Vice President of Medical Affairs at Johns Hopkins Bayview Medical Center. She also serves as Associate Chief Medical Officer of The Johns Hopkins Hospital. Her research interests include medical education and clinical outcomes after surgery. Dr. Clifton received her medical degree from the Johns Hopkins University School of Medicine and completed her residency in urology at the Mayo Clinic in Rochester, Minnesota. She completed her fellowship in Female Pelvic Medicine and Reconstructive Surgery at The Cleveland Clinic in Cleveland, Ohio. Dr. Clifton is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Urinary Incontinence, Obstructive Uropathy, Neurogenic Bladder, Sacral Nerve Stimulation, and Hormone Replacement Therapy (HRT). Dr. Clifton is board certified in American Board Of Urology.

Dr. Andrew J. Cohen is an Associate Professor of Urology at Johns Hopkins. He serves as the Division Director of Benign Urology and Director of Advanced Practice Providers at the Johns Hopkins Brady Urological Institute. He has a robust clinical practice focusing on complex genitourinary reconstruction. In particular, he has interest in the management of erectile dysfunction, urinary incontinence, stricture diseases of the urinary system, peyronie's disease, genital skin conditions, buried penis, urinary diversion, and other benign urologic conditions. He has extensive experience in robotic surgery. He also focuses on issues pertinent to cancer survivorship in men. He is well equipped to perform novel minimally invasive procedures such as endoscopic urethroplasty and robotic buccal ureteroplasty. He has an extensive research portfolio, with particular concentration in outcomes and safety research. Dr. Cohen received dual B.S. degrees summa cum laude from the University of Florida in Chemistry and Chemical Engineering, followed by an MD from the University of Chicago where he was inducted into the Alpha Omega Alpha Honor Society. His urologic training was pursued at the University of Chicago. Furthermore, he completed a fellowship in Genitourinary Reconstruction and Trauma at the University of California, San Francisco. Among many honors, he was invited to join the Trauma and Urologic Reconstructive Network of Surgeons in 2025. He was a also a recipient of the 'Rising Star' Award from the Society of Genitouinary Reconstructive Surgeons in 2025. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Urethral Stricture, Hydronephrosis, Obstructive Uropathy, Prostatectomy, and Lithotripsy. Dr. Cohen is board certified in American Board Of Urology.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is board certified in American Board Of Internal Medicine.

Mario Eisenberger is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Eisenberger is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, Hormone Replacement Therapy (HRT), and Prostatectomy.

Herbert Carter is a Urologist practicing medicine in Baltimore, Maryland. Dr. Carter is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Hydrocele, Prostatectomy, and Vasectomy.

Brad Lerner is a Urologist practicing medicine in Baltimore, Maryland. Dr. Lerner is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Enlarged Prostate (BPH), Familial Prostate Cancer, Prostate Cancer, Ureteroscopy, and Prostatectomy.

Jason Molitoris is a Radiologist and a Radiation Oncologist practicing medicine in Baltimore, Maryland. Dr. Molitoris is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Adult Soft Tissue Sarcoma, Familial Prostate Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Molitoris is board certified in American Board Of Radiology.

Adel Mandl is an Endocrinologist practicing medicine in Baltimore, Maryland. Dr. Mandl is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia, Prostate Cancer, and Pheochromocytoma.